Objectives Magnetic resonance elastography (MRE) provides multiple quantitative biomarkers for assessing chronic liver disease. This study evaluated the prognostic value of MRE-based long-term liver stiffness (LS) changes in chronic hepatitis C virus (HCV) infection and explored short-term viscosity changes (loss modulus, LM) for monitoring responses to direct-acting antiviral treatment (DAA-Tx). Materials and methods One hundred fifty-nine adults were included. We retrospectively analyzed 138 HCV participants with at least two 2D MREs, defining progression as an LS increase ΔLS ≥ 19% above baseline (LSB), predicting liver-related events (LREs) with Kaplan–Meier plots and Cox proportional hazards regression. We also prospectively analyzed 21 participants, 11 of whom underwent DAA-Tx and ten healthy controls. Dual-frequency 3D MRE-derived LS, LM, and damping ratio (DR) were compared at five time points during DAA-Tx. Results Among the 138 HCVs, 38 (27.5%) were progressors, with a ΔLS = 0.393 kPa/year; 11 developed LREs, showing a steeper rise of 0.614 kPa/year. LSB and the combination of LSB and ΔLS were significantly associated with LREs. Specifically, each 1 kPa increase in LSB was associated with doubled risk of developing LREs [adjusted hazard ratio (aHR) = 2.05; C-statistic = 0.831, p < 0.001]. The combination of LSB and ΔLS further improved predictive performance (aHR = 2.92; C-statistic = 0.883, p < 0.001). Progressors had a hazard ratio (HR) of 15.44 for developing cirrhosis (p < 0.001). LS decreased post-DAA-Tx, while LM initially increased (p < 0.05) and normalized by 12 months post-DAA-Tx. Conclusions Two-dimensional MRE-assessed longitudinal change in LS can predict future clinical events in HCV patients, providing better risk stratification than LS alone. Multiparametric dual-frequency 3D MRE has promise for short-term changes in treatment effects. Key Points <Emphasis Type="BoldItalic">Question</Emphasis> Accurately predicting clinical outcomes and monitoring direct-acting antiviral (DAA) treatment efficacy in HCV patients remains an unmet need. <Emphasis Type="BoldItalic">Findings</Emphasis> Longitudinal LS changes predict future clinical events in HCV patients. Multiparametric dual-frequency 3D MRE detects short-term inflammatory and treatment-related changes, enhancing disease monitoring. <Emphasis Type="BoldItalic">Clinical relevance</Emphasis> This study demonstrates longitudinal MRE as a reliable follow-up tool for chronic liver disease, enabling outcome prediction, risk stratification, and treatment monitoring, advancing personalized, non-invasive management for HCV patients. Graphical Abstract

Long-term clinical outcomes and short-term treatment efficacy evaluation based on longitudinal MR elastography in patients with chronic hepatitis C virus infection

期刊论文
发表日期：

2025年8月4日

查看全文

Caixin Qiu,
Hao Wu,
Peng Xu,
Nana K. Owusu,
Kevin J. Glaser,
Jiahui Li,
Douglas A. Simonetto,
Sudhakar K. Venkatesh,
Wen Shen,
Armando Manduca,
Vijay H. Shah,
Richard L. Ehman,
Meng Yin

摘要

Objectives

Magnetic resonance elastography (MRE) provides multiple quantitative biomarkers for assessing chronic liver disease. This study evaluated the prognostic value of MRE-based long-term liver stiffness (LS) changes in chronic hepatitis C virus (HCV) infection and explored short-term viscosity changes (loss modulus, LM) for monitoring responses to direct-acting antiviral treatment (DAA-Tx).

Materials and methods

One hundred fifty-nine adults were included. We retrospectively analyzed 138 HCV participants with at least two 2D MREs, defining progression as an LS increase ΔLS ≥ 19% above baseline (LS_B), predicting liver-related events (LREs) with Kaplan–Meier plots and Cox proportional hazards regression. We also prospectively analyzed 21 participants, 11 of whom underwent DAA-Tx and ten healthy controls. Dual-frequency 3D MRE-derived LS, LM, and damping ratio (DR) were compared at five time points during DAA-Tx.

Results

Among the 138 HCVs, 38 (27.5%) were progressors, with a ΔLS = 0.393 kPa/year; 11 developed LREs, showing a steeper rise of 0.614 kPa/year. LS_B and the combination of LS_B and ΔLS were significantly associated with LREs. Specifically, each 1 kPa increase in LS_B was associated with doubled risk of developing LREs [adjusted hazard ratio (aHR) = 2.05; C-statistic = 0.831, p < 0.001]. The combination of LS_B and ΔLS further improved predictive performance (aHR = 2.92; C-statistic = 0.883, p < 0.001). Progressors had a hazard ratio (HR) of 15.44 for developing cirrhosis (p < 0.001). LS decreased post-DAA-Tx, while LM initially increased (p < 0.05) and normalized by 12 months post-DAA-Tx.

Conclusions

Two-dimensional MRE-assessed longitudinal change in LS can predict future clinical events in HCV patients, providing better risk stratification than LS alone. Multiparametric dual-frequency 3D MRE has promise for short-term changes in treatment effects.

Key Points

Question Accurately predicting clinical outcomes and monitoring direct-acting antiviral (DAA) treatment efficacy in HCV patients remains an unmet need.

Findings Longitudinal LS changes predict future clinical events in HCV patients. Multiparametric dual-frequency 3D MRE detects short-term inflammatory and treatment-related changes, enhancing disease monitoring.

Clinical relevance This study demonstrates longitudinal MRE as a reliable follow-up tool for chronic liver disease, enabling outcome prediction, risk stratification, and treatment monitoring, advancing personalized, non-invasive management for HCV patients.

Graphical Abstract